Litcius/Paper detail

Partial treatment response to capmatinib in <i>MET</i>-amplified metastatic intrahepatic cholangiocarcinoma: case report &amp; review of literature

Daniel S. Lefler, Marni Brisson Tierno, Babar Bashir

2022Cancer Biology & Therapy18 citationsDOIOpen Access PDF

Abstract

gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided a partial response after cessation of chemotherapy.

Topics & Concepts

Intrahepatic CholangiocarcinomaMedicineGemcitabineChemotherapyMalignancyTolerabilityOncologyInternal medicineImmunotherapyTargeted therapyC-MetPaclitaxelCancer researchCancerAdverse effectHepatocyte growth factorReceptorCholangiocarcinoma and Gallbladder Cancer StudiesLiver physiology and pathologyPediatric Hepatobiliary Diseases and Treatments
Partial treatment response to capmatinib in <i>MET</i>-amplified metastatic intrahepatic cholangiocarcinoma: case report &amp; review of literature | Litcius